239 related articles for article (PubMed ID: 18298894)
1. Arsenic trioxide: safety issues and their management.
Au WY; Kwong YL
Acta Pharmacol Sin; 2008 Mar; 29(3):296-304. PubMed ID: 18298894
[TBL] [Abstract][Full Text] [Related]
2. Arsenic trioxide in the treatment of haematological malignancies.
Kwong YL
Expert Opin Drug Saf; 2004 Nov; 3(6):589-97. PubMed ID: 15500417
[TBL] [Abstract][Full Text] [Related]
3. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
4. Arsenicals in hematologic cancers.
Novick SC; Warrell RP
Semin Oncol; 2000 Oct; 27(5):495-501. PubMed ID: 11049017
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral injection of arsenic to enhance antitumor efficacy in human esophageal carcinoma cell xenografts.
Shen ZY; Zhang Y; Chen JY; Chen MH; Shen J; Luo WH; Zeng Y
Oncol Rep; 2004 Jan; 11(1):155-9. PubMed ID: 14654919
[TBL] [Abstract][Full Text] [Related]
6. Significance of intracellular arsenic trioxide for therapeutic response in acute promyelocytic leukemia.
Sahu GR; Jena RK
Am J Hematol; 2005 Feb; 78(2):113-6. PubMed ID: 15682419
[TBL] [Abstract][Full Text] [Related]
7. Unusual effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents.
Drolet B; Simard C; Roden DM
Circulation; 2004 Jan; 109(1):26-9. PubMed ID: 14691044
[TBL] [Abstract][Full Text] [Related]
8. Opposing effects of arsenic trioxide on hepatocellular carcinomas in mice.
Liu B; Pan S; Dong X; Qiao H; Jiang H; Krissansen GW; Sun X
Cancer Sci; 2006 Jul; 97(7):675-81. PubMed ID: 16827809
[TBL] [Abstract][Full Text] [Related]
9. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide: new clinical experience with an old medication in hematologic malignancies.
Douer D; Tallman MS
J Clin Oncol; 2005 Apr; 23(10):2396-410. PubMed ID: 15800332
[TBL] [Abstract][Full Text] [Related]
11. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
12. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of intravenous arsenic trioxide in the treatment of acute promyelocytic leukemia.
Ni J; Chen G; Shen Z; Li X; Liu H; Huang Y; Fang Z; Chen S; Wang Z; Chen Z
Chin Med J (Engl); 1998 Dec; 111(12):1107-10. PubMed ID: 11263375
[TBL] [Abstract][Full Text] [Related]
14. Systemic availability of arsenic from oral arsenic-trioxide used to treat patients with hematological malignancies.
Kumana CR; Au WY; Lee NS; Kou M; Mak RW; Lam CW; Kwong YL
Eur J Clin Pharmacol; 2002 Nov; 58(8):521-6. PubMed ID: 12451429
[TBL] [Abstract][Full Text] [Related]
15. Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
Verstovsek S; Giles F; Quintás-Cardama A; Perez N; Ravandi-Kashani F; Beran M; Freireich E; Kantarjian H
Hematol Oncol; 2006 Dec; 24(4):181-8. PubMed ID: 16783836
[TBL] [Abstract][Full Text] [Related]
16. Morphological and biochemical changes induced by arsenic trioxide in neuroblastoma cell lines.
Ryu KH; Woo SY; Lee MY; Jung YJ; Yoo ES; Seoh JY; Kie JH; Shin HY; Ahn HS
Pediatr Hematol Oncol; 2005; 22(7):609-21. PubMed ID: 16166054
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide: new preparation. Acute promyelocytic leukaemia: encouraging results but persistent doubts.
Prescrire Int; 2004 Aug; 13(72):135-7. PubMed ID: 15532137
[TBL] [Abstract][Full Text] [Related]
18. Arsenic trioxide in the management of acute promyelocytic leukaemia.
Mathews V; Chandy M; Srivastava A
Natl Med J India; 2001; 14(4):215-22. PubMed ID: 11547528
[TBL] [Abstract][Full Text] [Related]
19. Arsenic-induced APL differentiation in cerebrospinal fluid.
Helwig A; Klemm M; Schüttig R; Röllig C; Wassilew N; Ehninger G; Illmer T
Leuk Res; 2007 May; 31(5):703-5. PubMed ID: 16876245
[TBL] [Abstract][Full Text] [Related]
20. Inhibition on LS-174T cell growth and activity of telomerase in vitro and in vivo by arsenic trioxide.
Wang X; Wang G; Dong D; Fu S; Yang B
Exp Toxicol Pathol; 2008 Sep; 60(6):481-8. PubMed ID: 18606528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
